Semaglutide is a single peptide molecule sold under three FDA-approved brand names, each carrying its own indication, route, and dosing ceiling, with no approved generic on the market as of mid-2026. The names are not interchangeable on a prescription: Ozempic, Wegovy, and Rybelsus deliver the same drug but differ in approved use, delivery, and titration, so the brand written on a script signals the dose range and the indication, not just the active ingredient. All three are manufactured by Novo Nordisk.
Semaglutide reaches patients through three FDA-approved Novo Nordisk brands, Ozempic, Wegovy, and Rybelsus, with no approved generic equivalent available as of mid-2026.
Three branded semaglutide products hold FDA approval, and each was reviewed and labeled independently because each was studied in its own trial program, at its own dose range, for its own population. The practical consequence is documented plainly in the labeling: the brand name, not the generic name semaglutide, signals the approved use, the dosing ceiling, and in Wegovy's case the eligible age range.
Ozempic and Rybelsus are FDA-approved for type 2 diabetes while Wegovy is FDA-approved for chronic weight management, and each label was reviewed independently from its own clinical trial program.
The defining contrast in the labeling is route and rhythm: Rybelsus is a tablet taken once every morning, while Ozempic and Wegovy are injections taken once a week. The daily schedule exists because the oral route loses far more drug to digestion, and Rybelsus carries strict administration rules the injectables do not, since food and liquid in the stomach sharply cut how much of the peptide is absorbed. As of mid-2026 Rybelsus is approved for type 2 diabetes glycemic control, not for weight management.
Rybelsus is a once-daily tablet requiring an empty stomach and a 30-minute fast, while Ozempic and Wegovy are once-weekly injections, and the oral milligram strengths do not map onto injectable doses because oral absorption is far lower.
Injectable semaglutide is deliberately started low and stepped up slowly, because the gastrointestinal side effects of this drug class are worst when blood levels climb too fast. The labeling describes a 0.25 milligram weekly starting dose meant only to let the body adjust, with Ozempic moving up toward 2 milligrams and Wegovy climbing a longer ladder to a 2.4 milligram target, and clinicians are instructed to slow or pause the step-up when a patient is not tolerating a level rather than push ahead on a fixed calendar.
The labeled injectable titration starts at 0.25 milligram weekly and steps up over roughly four to five months to a 2-milligram ceiling for Ozempic or a 2.4-milligram maintenance dose for Wegovy, with faster escalation linked to severe nausea, vomiting, and diarrhea.
Peptides like semaglutide are normally destroyed by stomach acid and are too large to cross the gut wall, so the published formulation of Rybelsus relies on a built-in absorption enhancer to get any drug into the bloodstream at all. The tablet is co-formulated with the permeation enhancer SNAC, sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, which locally raises the pH around the tablet and transiently helps the peptide pass through the stomach lining before it is degraded. Even under ideal timing the amount reaching the blood is small and variable, which is why the oral milligram numbers are not comparable to injectable doses.
Rybelsus is co-formulated with the SNAC permeation enhancer and comes in 3, 7, and 14 milligram strengths, and because absorption depends on a near-empty low-fluid stomach, the timing instructions are treated as essential rather than optional.
The published regulatory record is unambiguous on this point: compounded semaglutide is not an FDA-approved product, and its availability surged for one specific reason. Federal rules let compounding pharmacies prepare a version of a drug that is otherwise commercially unavailable when that drug sits on the FDA's official shortage list, and the branded injectables spent extended periods on that list as demand outstripped supply. The FDA repeatedly warned that compounded salt forms such as semaglutide sodium and acetate had not been shown safe or effective and carried real dosing-error and contamination hazards because they bypass agency review.
Compounded semaglutide is not FDA-approved; its availability is legally tied to the FDA shortage list, and the FDA has warned that compounded salt forms have not been shown to be safe or effective and carry dosing-error and contamination risk.
As of mid-2026 there is no FDA-approved generic equivalent of semaglutide, and the branded products remain the only agency-reviewed sources of the drug. The molecule is shielded by a layered set of protections, composition-of-matter and formulation patents, method-of-use patents tied to specific indications, and regulatory exclusivity, and because semaglutide is a manufactured peptide a competitor cannot file a standard generic showing simple chemical identity. Genuine generic or biosimilar competition is generally expected only as the principal patents and exclusivities lapse later in the decade, with timing that varies by country.
No FDA-approved generic semaglutide exists as of mid-2026, because the molecule is protected by layered patents and regulatory exclusivity that are generally expected to lapse only in the latter part of the decade.
Beyond the three standalone brands, the published and developmental record shows semaglutide appearing in combination and next-generation formulations that broaden how the molecule is delivered. The clearest fixed-dose example is a once-weekly injectable pairing semaglutide with the basal insulin icodec for type 2 diabetes, aimed at patients already on or needing insulin, while the manufacturer has also pursued higher-dose oral semaglutide intended to push the daily tablet toward weight-management efficacy the current Rybelsus strengths do not reach. These programs extend the molecule into new use cases rather than replacing Ozempic, Wegovy, or Rybelsus.
Semaglutide also appears in a fixed-dose combination with the basal insulin icodec and in higher-dose oral pipeline programs, which extend the molecule into new populations rather than replacing Ozempic, Wegovy, or Rybelsus.
Educational use only. This article describes what the published scientific and clinical literature reports about Semaglutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
